Market Overview

Sequenom Can't Go Back; Ladenburg Analysts Downgrade To Sell

Sequenom Can't Go Back; Ladenburg Analysts Downgrade To Sell

  • Shares of Sequenom, Inc. (NASDAQ: SQNM) are down roughly 13 percent on Tuesday trading, following the company's investor day event on Monday.
  • Following the gathering, analysts at Ladenburg Thalmann downgraded shares of the company from Neutral to Sell, setting a $0.90 price target.
  • According to a report issued Tuesday, the demotion was based on what the firm conceives as the lack of “a credible plan to address eroding NIPT market share, limited disclosure on the company's strategy for entering the liquid biopsy market and minimal effort to rebuild damaged investor credibility following a recent reduction in 2015 revenue guidance and abrupt leadership transition.”
  • Given the absence of a credible commercial strategy, analysts Kevin DeGeeter and James Colby see “minimal near-term prospects for sales growth and significant risk of growing operating losses and SQNM's need to raise capital through dilutive equity offerings.”

    Without a plan to lead them to profitability, the experts believe the company could only be sold at a depressed valuation. Moreover, Sequenom only has $129 million in convertible debt outstanding due in 2018. In Ladenburg’s view, any change of control would imply a significant portion of any proceeds probably being captured by note holders.

    The report highlighted three key issues in their Sell thesis:

    • 1) The company’s reboot will be driven by technology, and not a commercial reform. However, the analysts think the market is not “suited for a technology-driven development strategy.” Additionally, they do not believe the company is poised to be “among the first to market with liquid biopsies.”
    • 2) Ladenburg contended that Sequenom “lost its market leadership in NIPT to competitors with more flexible commercial strategies. With the renewed focus on internal product development without first fixing shortcomings in commercial execution, in our view, SQNM risks repeating the past in a new vertical (liquid biopsies),” the experts added.
    • 3) The management’s target of $500 million in revenue by 2020 looks quite aggressive.

    Disclosure: Javier Hasse holds no positions in any of the securities mentioned above.

    Image Credit: Public Domain

    Latest Ratings for SQNM

    Mar 2016Ladenburg ThalmannUpgradesSellNeutral
    Sep 2015JefferiesDowngradesBuyHold
    Sep 2015Ladenburg ThalmannDowngradesSell

    View More Analyst Ratings for SQNM
    View the Latest Analyst Ratings


    Related Articles (SQNM)

    View Comments and Join the Discussion!

    Posted-In: Analyst Color Biotech Downgrades Health Care Small Cap Analysis Price Target Analyst Ratings Trading Ideas Best of Benzinga

    Latest Ratings

    SYFJP MorganUpgrades46.0
    SESCIBCInitiates Coverage On4.0
    SCJP MorganUpgrades
    ROKUJP MorganInitiates Coverage On475.0
    View the Latest Analytics Ratings
    Don't Miss Any Updates!
    News Directly in Your Inbox
    Subscribe to:
    Benzinga Premarket Activity
    Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
    Market in 5 Minutes
    Everything you need to know about the market - quick & easy.
    Fintech Focus
    A daily collection of all things fintech, interesting developments and market updates.
    Thank You

    Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at